NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)

 
ARIA Technical Analysis
5
As on 15th Feb 2017 ARIA Share Price closed @ 23.99 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 11.34 & Strong Buy for SHORT-TERM with Stoploss of 18.18 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

ARIA Share Price

Open 23.95 Change Price %
High 23.99 1 Day 0.04 0.17
Low 23.94 1 Week 0.00 0.00
Close 23.99 1 Month 0.00 0.00
Volume 7192149 1 Year 11.56 93.00
52 Week High 23.99 | 52 Week Low 11.69
 
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
INTC 45.49 2.52%
 
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
 
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
 
 
ARIA
Daily Charts
ARIA
Intraday Charts
Whats New @
Bazaartrend
ARIA
Free Analysis
 
ARIA Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
RESISTANCE24.04
RESISTANCE24.02
SUPPORT23.96
SUPPORT23.94
SUPPORT0.00
SUPPORT0.00
 
ARIA Target for Month October
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
ARIA Weekly Target
4th UP TARGET0.00
3rd UP TARGET0.00
2nd UP TARGET0.00
1st UP TARGET0.00
1st DOWN TARGET0.00
2nd DOWN TARGET0.00
3rd DOWN TARGET0.00
4th DOWN TARGET0.00
 
ARIA Target for Year 2020
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
 
ARIA Other Details
Segment EQ
Market Capital 3671460096.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
ARIA Address
ARIA
26 Landsdowne Street
Cambridge, MA 02139
United States
Phone: 617-494-0400
Fax: 617-494-8144
 
ARIA Latest News
 
Your Comments and Response on ARIAD Pharmaceuticals, Inc.
 
ARIA Business Profile
ARIAD Pharmaceuticals, Inc. (ARIAD), incorporated on on April 12, 1991, is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. ARIAD’s first medicine, Iclusig, is approved in the United States for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy. As of January 11, 2013, additional clinical trials of Iclusig in other cancers were ongoing. As of January 11, 2013, ARIAD also studied AP26113, another molecularly targeted medicine, in certain forms of lung cancer. As of January 11, 2013, the Company’s pipeline contained four compounds: ponatinib, AP26113, ridaforolimus and AP1903. AP26113 is a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). AP1903 is a dimerizer drug licensed to Bellicum Pharmaceuticals, Inc. In December 2012, the Company was granted accelerated approval of Iclusig ponatinib for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy. Ponatinib is a BCR-ABL inhibitor that also selectively inhibits certain other tyrosine kinases in preclinical studies, including FLT3, RET, KIT, and the members of the FGFR, PDGFR and VEGFR families of kinases. The EPIC (Evaluation of Ponatinib versus Imatinib inChronic Myeloid Leukemia) trial is designed to provide definitive clinical data to support regulatory approval of ponatinib in treatment-nave CML patients. The PACE (Ponatinib Ph+ ALL and CML Evaluation) trial is a pivotal Phase 2 clinical trial of the Company’s investigational pan-BCR-ABL inhibitor, ponatinib (formerly AP24534).
 
2005-2019 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service